Vivos Therapeutics (VVOS)

• Market cap: $12.4M
• 1 day: 0.96%
• 5 days: -11.39%
• 1 month: -41.34%
• 3 months: -63.41%
• 6 months: -13.93%
• Year to date: -50.59%
• 1 year: -21.05%
• 5 years: -99.07%
• 10 years: -99.07%
• Sector: Healthcare
• Industry: Medical Devices

About: Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Employees: 109

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

218% more capital invested

Capital invested by funds: $631K [Q3] → $2.01M (+$1.37M) [Q4]

4.52% more ownership

Funds ownership: 5.14% [Q3] → 9.66% (+4.52%) [Q4]

13% less funds holding

Funds holding: 23 [Q3] → 20 (-3) [Q4]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $6.20 195% upside
• Avg. target: $6.20 195% upside
• High target: $6.20 195% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Ascendiant Capital Lucas Ward 25% 1-year accuracy 3 / 12 met price target

195% upside $6.20

Buy Maintained

15 Apr 2025